Vaccination with agonist peptide PSA:154–163(155L) derived from prostate specific antigen induced CD8 T cell response to the native peptide PSA:154–163 but failed to induce the reactivity against tumor targets expressing PSA: a Phase 2 study in patients with recurrent prostate cancer

We conducted a clinical trial of peptide PSA:154–163(155L) vaccination in HLA-A2 patients with detectable and rising serum PSA after radical prostatectomy for prostate cancer (Clinicaltrials.gov identifier NCT00109811). The trial was a single dose-level, Phase II pilot trial of 1 mg of PSA154–163(15...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kouiavskaia, D. V., Berard, C. A., Datena, E., Hussain, A., Dawson, N., Klyushnenkova, E. N., Alexander, R. B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2758610/
https://ncbi.nlm.nih.gov/pubmed/19483644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181a80e0d
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados